- Home
- CHRS vs DERM Comparison
CHRS vs DERM Comparison
Compare CHRS & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DERM
- Stock Information
- Founded
- CHRS 2010
- DERM 2014
- Country
- CHRS United States
- DERM United States
- Employees
- CHRS N/A
- DERM N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- DERM Health Care
- Exchange
- CHRS Nasdaq
- DERM Nasdaq
- Market Cap
- CHRS 159.2M
- DERM 165.6M
- IPO Year
- CHRS 2014
- DERM 2021
- Fundamental
- Price
- CHRS $1.35
- DERM $7.05
- Analyst Decision
- CHRS Strong Buy
- DERM Strong Buy
- Analyst Count
- CHRS 4
- DERM 3
- Target Price
- CHRS $4.51
- DERM $12.67
- AVG Volume (30 Days)
- CHRS 1.2M
- DERM 131.2K
- Earning Date
- CHRS 11-05-2025
- DERM 11-11-2025
- Dividend Yield
- CHRS N/A
- DERM N/A
- EPS Growth
- CHRS N/A
- DERM N/A
- EPS
- CHRS 1.55
- DERM N/A
- Revenue
- CHRS $272,209,000.00
- DERM $56,397,000.00
- Revenue This Year
- CHRS N/A
- DERM $28.10
- Revenue Next Year
- CHRS $109.48
- DERM $53.84
- P/E Ratio
- CHRS $0.87
- DERM N/A
- Revenue Growth
- CHRS 52.33
- DERM N/A
- 52 Week Low
- CHRS $0.66
- DERM $3.54
- 52 Week High
- CHRS $2.43
- DERM $8.90
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- DERM 45.87
- Support Level
- CHRS $1.23
- DERM $7.00
- Resistance Level
- CHRS $1.40
- DERM $7.12
- Average True Range (ATR)
- CHRS 0.08
- DERM 0.27
- MACD
- CHRS -0.00
- DERM -0.01
- Stochastic Oscillator
- CHRS 72.13
- DERM 26.75
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.